UK markets close in 7 hours 49 minutes
  • FTSE 100

    6,919.51
    -18.73 (-0.27%)
     
  • FTSE 250

    22,314.42
    -50.45 (-0.23%)
     
  • AIM

    1,261.64
    -2.05 (-0.16%)
     
  • GBP/EUR

    1.1524
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.3891
    +0.0048 (+0.35%)
     
  • BTC-GBP

    34,734.04
    -4,750.39 (-12.03%)
     
  • CMC Crypto 200

    1,092.30
    -150.75 (-12.13%)
     
  • S&P 500

    4,134.98
    -38.44 (-0.92%)
     
  • DOW

    33,815.90
    -321.41 (-0.94%)
     
  • CRUDE OIL

    62.04
    +0.61 (+0.99%)
     
  • GOLD FUTURES

    1,781.90
    -0.10 (-0.01%)
     
  • NIKKEI 225

    29,020.63
    -167.54 (-0.57%)
     
  • HANG SENG

    28,981.13
    +225.79 (+0.79%)
     
  • DAX

    15,299.78
    -20.74 (-0.14%)
     
  • CAC 40

    6,280.81
    +13.53 (+0.22%)
     

PCI Biotech to present at European Biotech Investor Days 2021

  • Oops!
    Something went wrong.
    Please try again later.
PCI Biotech Holding ASA
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Oslo (Norway), 6 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it will present at the European Biotech Investor Days 2021, a US based online event taking place April 7-8, 2021 and hosted by Goodwin, Solebury Trout, Deutsche Bank and Nasdaq.

On Thursday, April 8, 2021 at 15:00 (CEST), Dr. Per Walday, CEO, will present an overview of PCI Biotech’s proprietary platform technology via a general company presentation.

The presentation can be accessed live through this link https://showroom.troutaccess.com/app?iframe=1#/webcast/GHAQ5D

The presentation slides will be made available on PCI Biotech’s website (www.pcibiotech.com) under “Other presentations” after the event.

Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.